http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1841453-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dea036d1b8d39c3e2259ef477ab4657c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6f5aaa9266073261eeb6d2839429a4d1 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M1-3679 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2006-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23dce8aa2b78df4c854842cbb4948da6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f22f53e49f5b68063db11161b7f42fc2 |
| publicationDate | 2007-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1841453-A2 |
| titleOfInvention | Treatment of pre-eclampsia in pregnant women using targeted apheresis |
| abstract | This invention uses 'targeted apheresis' to treat pregnant women who are at risk of developing eclampsia. 'Targeted Apheresis' is a process whereby the sFlt-1 receptors responsible for causing the disease symptoms are selectively removed from the blood by passing the blood through a cartridge containing either immobilized PIGF, and/or through a cartridge containing immobilized anti-sFlt-1 antibody. The sFlt-1 receptor is bound out and the cleaned blood is returned to the patient Removal of circulating sFlt-1 receptors will diminish the risk of developing eclampsia during pregnancy. |
| priorityDate | 2005-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 52.